Moss, 29 March 2022
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and efficient diagnostics for better treatment decisions, is pleased to announce the release of the novel CE marked SARS-CoV-2 Total Antibody Immunoassay. This is an open channel immunoassay for use on high-throughput clinical chemistry analysers.
“The need for reliable high-throughput antibody tests increases in the post-vaccine phase of the COVID-19 pandemic, to follow, document and manage efficient population immunity. With up to 2000 tests per hour we are confident that our new SARS-CoV-2 test can increase capacity and laboratory efficiency significantly. Our assay can be used on all instrument platforms with no additional infrastructure or workflow costs.”, says CEO Hilja Ibert in Gentian Diagnostics.
Gentian’s SARS-CoV-2 Total Antibody Immunoassay captures the full immune response detecting total antibody levels targeting the S1-subunit of SARS-CoV-2. The assay is fully aligned with the WHO International Standard for quantitative measurements.
The Gentian assay is easily accessible and efficient and is intended to identify patients with an adaptive immune response to SARS-CoV-2 that indicates recent or prior infection or a successful response to vaccination. It will provide a powerful high-throughput test for community management of COVID-19 through long-term monitoring of natural and vaccine-related immune response, with the potential to aid future vaccination evaluation and strategy.
Gentian’s turbidimetric SARS-CoV-2 Total Antibody Immunoassay has been developed in collaboration with the University in Tromsø (UiT). The SARS-CoV-2 test will add to Gentian’s diagnostics test portfolio including four established products, and the GCAL® infection and inflammation assay which is in market development. Initial market focus will be on the Nordic countries, with subsequent commercial expansion into additional European geographies.
For further information, please contact:
Hilja Ibert, CEO
+47 919 05 242 (mobile)
Njaal Kind, CFO and COO
+47 919 06 525 (mobile)
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.